Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its Existing Partnership

 Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its Existing Partnership

Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its Existing Partnership

Shots:

  • As per the first agreement, Ardelyx to receive $10M for research and is eligible to receive ~10.5M upfront and up to $500M as development & commercialization milestone and will execute research in collaboration with Kyowa Kirin for only two targets
  • Following the end of the research period, Kyowa Kirin to get an option to license any candidates for the development & commercialization in selected territories. Ardelyx will receive $20M as equity investment from Kyowa Kirin for its 2,873,563 shares at $6.96/share, under the second agreement
  •  In Nov’2017, Ardelyx and Kyowa Kirin collaborated to develop & commercialize Tenapanor for cardiorenal diseases, including hyperphosphatemia in Japan which granted Kyowa Kirin an exclusive right to develop & commercialize Tenapanor in Japan

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Cube Brush

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post